Close X
Horizons >  Film series >  Expert Insights
 

FLOW with Peter Rossing

FLOW was the first randomised controlled trial to evaluate an GLP-1 receptor agonist (RA) in patients living with type 2 diabetes and chronic kidney disease, and it was stopped early due to efficacy. In this Expert Insights episode, FLOW steering group member Peter Rossing presents key results of the study and also discusses open questions like: Will these effects translate to other incretin-based therapies? And: Will patients without type 2 diabetes benefit as well?